Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is a promising biotech company with a positive outlook due to their strong pipeline of potential immunotherapy treatments, successful partnerships, and low expenses. However, there are potential risks such as legal disputes that could affect the stock price. Investors should closely monitor the results of the ongoing clinical trials for colon cancer and closely watch for any updates on ongoing legal matters.

Bears say

AnaptysBio is highly dependent on Jemperli, with a disconnect from investors who are not considering potential revenue inflection points. The company's royalty deal with Sagard Healthcare Royalty Partners has a cash inflow of $250 million, with an estimated remaining amount of $325 million to be paid off in the 2Q27 range. However, with only early data available, the potential for a non-operative approach may suggest limited demand for the company's product, and the lack of significant adverse events means there may not be enough data to support the potential of AnaptysBio's treatment.

AnaptysBio (ANAB) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 10 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.